Overall, in this study, we show a dual mechanism of activation of the Shh pathway in thyroid tumors: a ligand-independent activation, caused by interaction with RAS/BRAF/MEK oncogenic cascade, and a ligand-dependent activation sustained by ligand (Shh) secretion from fibrotic stroma, promoting cancer cell migration and invasion. This evidence concerns the gene MAP2K7 and thyroid tumor.